The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESSO 43 | Developing European guidelines for defining and treating oligometastatic esophagogastric cancer
Richard Hillegersberg, MD, PhD, UMC Utrecht, Utrecht, Netherlands, discusses a session on oligometastatic disease in upper gastrointestinal cancers at ESSO 43, emphasizing the OMEC-project, which aims to develop a multidisciplinary European consensus statement on the definition, diagnosis, and treatment for oligometastatic esophagogastric cancer across 50 European expert centers. He highlights the project’s multiple phases, including a randomized control trial on the duration of preoperative chemotherapy in relation to local treatment. This interview took place at the ESSO 43 congress in Antwerp, Belgium.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
